Why is Eli Lilly and Company (LLY) One of the Best Long Term Low Volatility Stocks to Buy Right Now?

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P. Morgan analyst Chris Schott maintained a bullish stance on Eli Lilly and Company (NYSE:LLY), keeping his Buy rating.

The same day, Eli Lilly and Company (NYSE:LLY) announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial, showing that “two years of adjuvant Verzenio plus endocrine therapy (ET) reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer”.

Management reported that the results were published in the Annals of Oncology and are being submitted to regulatory health authorities across the globe.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.